PLUS1
60.51
-0.50 (-0.82%)
-0.50 (-0.82%)
Upgrade to Real-Time
Regular Market
Low
58.79
High
137.61
Best deals to access real time data! |
|
Ultimate Trader (Monthly)
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
Big Cap Pro
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Emergent Biosolutions Inc | EBS | NYSE | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded  |
|
|---|---|---|---|---|
| -0.50 | -0.82% | 60.51 | 13:50:41 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 60.31 | 60.00 | 61.88 | 61.01 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 5,867 | 379,603 | $ 60.73 | $ 23,052,005 | 1,005,175 | 58.79 - 137.61 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 13:50:38 | 2 | $ 60.53 | USD |
Emergent Biosolutions Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 3.24B | 53.59M | 43.18M | $ 1.56B | $ 353.08M | 5.66 | 8.50 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | 10.16k | 3.80% |
Emergent Biosolutions News
| Date | Time | Source | News Article |
|---|---|---|---|
| 5/06/2021 | 06:30 | GlobeNewswire Inc. | Emergent BioSolutions to Hold Virtual Annual Meeting of.. |
| 5/05/2021 | 16:05 | GlobeNewswire Inc. | Emergent BioSolutions to Participate in Investor Conferences |
| 4/30/2021 | 12:46 | Seeking Alpha | CDC allocating J&J vaccine again, but still at low numbers |
| 4/30/2021 | 06:04 | Edgar (US Regulatory) | Quarterly Report (10-q) |
| 4/29/2021 | 16:35 | Seeking Alpha | Emergent Biosolutions EPS beats by $0.36, misses on revenue |
| 4/29/2021 | 16:05 | GlobeNewswire Inc. | Emergent BioSolutions Reports Financial Results for First.. |
| 4/28/2021 | 17:35 | Seeking Alpha | Emergent Biosolutions Q1 2021 Earnings Preview |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical EBS Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 62.90 | 63.25 | 58.79 | 61.11 | 843,816 | -2.39 | -3.8% |
| 1 Month | 79.75 | 79.75 | 58.79 | 67.29 | 1,033,643 | -19.24 | -24.13% |
| 3 Months | 121.01 | 127.20 | 58.79 | 82.24 | 859,236 | -60.50 | -50.0% |
| 6 Months | 93.74 | 127.20 | 58.79 | 87.92 | 700,109 | -33.23 | -35.45% |
| 1 Year | 79.50 | 137.61 | 58.79 | 92.88 | 729,563 | -18.99 | -23.89% |
| 3 Years | 49.20 | 137.61 | 39.11 | 73.92 | 498,486 | 11.31 | 22.99% |
| 5 Years | 38.00 | 137.61 | 24.47 | 61.30 | 447,196 | 22.51 | 59.24% |
Emergent Biosolutions Description
| Emergent BioSolutions offers public health products to government and healthcare providers. The company has four main units: vaccines, which produces specialty vaccines for public health threats; devices, such as nasal sprays, skin lotions, and injections; therapeutics, which includes antibody-based treatments; and contract development and manufacturing, which brings treatments to market through collaboration with the pharmaceutical and biotechnology industries and the United States government. Most revenue comes from U.S. government purchases of vaccine, device, and therapeutic products. |
